Skip to main content

Holiday schedule

Our Patient Service Centers will be closed on Wednesday, December 25, 2024 in observance of Christmas and Wednesday, January 1, 2025 in observance of New Year's Day. Have a healthy, happy holiday.

Hide
Quest Diagnostics

Non-lipid markers for CVD

Non-lipid markers for CVD

For some patients, the only indication of poor clopidogrel response to PLAVIX® (clopidogrel bisulfate) may be an atherothrombotic event, such as a heart attack or stroke. AccuType® CP enables early identification of patients who are predisposed to poor therapy response.

PLAVIX is indicated for the reduction of atherothrombotic events for patients with a history of recent myocardial infarction, stroke, or established peripheral arterial disease, as well as patients who are to be managed with percutaneous coronary intervention.1 It is marketed in the US under the trade name PLAVIX by Bristol-Myers Squibb and Sanofi-Aventis pharmaceuticals.2

AccuType® CP: Clopidogrel Response Testing
Importance of Genotyping


This information is provided for informational purposes only and is not intended as medical advice. A physician’s test selection and interpretation, diagnosis, and patient management decisions should be based on his/her education, clinical expertise, and assessment of the patient.

 

References

  1. FDA approves new indication for Plavix® (clopidogrel bisulfate) offering new option for patients with most severe type of heart attack. Sanofi-Aventis. Accessed June 29, 2021. https://www.news.sanofi.us/press-releases?item=118386
  2. Sanofi-Aventis and Bristol-Meyers Squibb announce important updates to PLAVIX® U.S. prescribing information. Sanofi-Aventis. March 12, 2010. Accessed June 29, 2021. https://www.news.sanofi.us/press-releases?item=118518

Questions?

Your Quest account representative can provide additional information on our cardiovascular testing solutions.

Contact Us

Cardiovascular

Resources

For your team: a treatment guide to lipid disorders

How to read your patient’s Cardio IQ® report

For patients: how Cardio IQ® makes a difference

For patients: contacting a 4myheart® expert

 

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.